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 In a companion article, we synthesized current clinical and preclinical data to formulate hypoth-
eses about the etiology of drug administration catheter-tip inflammatory masses. In this article, we com-




 We reviewed published and unpublished case reports and our own experiences to find meth-
ods to diagnose and treat catheter-tip inflammatory masses in a manner that minimized adverse neu-
rological sequelae. We also formulated hypotheses about theoretical ways to mitigate, and possibly,




 Human cases have occurred only in patients with chronic pain who received intrathecal opioid
drugs, alone or mixed with other drugs, or in patients who received agents that were not labeled for
long-term intrathecal use. Most patients had noncancer pain owing to their large representation among
the population with implanted pumps. Such patients also had a longer life expectancy and exposure to
intrathecal drugs, and they received higher daily doses than patients with cancer pain. Clues to diagnosis
included the loss of analgesic drug effects accompanied by new, gradually progressive neurological
symptoms and signs. When a mass was diagnosed before it filled the spinal canal or before it caused se-
vere neurological symptoms, open surgery to remove the mass often was not required. Anecdotal re-
ports and the authors’ experiences suggest that cessation of drug administration through the affected




 Attentive follow-up and maintenance of an index of suspicion should permit timely diag-
nosis, minimally invasive treatment, and avoidance of neurological injury from catheter-tip inflamma-
tory masses. Whenever it is feasible, positioning the catheter in the lumbar thecal sac and/or keeping
the daily intrathecal opioid dose as low as possible for as long possible may mitigate the seriousness,









The first case of an inflammatory mass at the tip of
an intrathecal morphine infusion catheter to treat
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chronic intractable pain was reported by North et
al. in 1991 [1]. More recently, Coffey and Burchiel
analyzed 41 cases compiled from the medical litera-
ture (as of November 2000) and from reports to
Medtronic, Inc. (Minneapolis, MN) or to the U.S.
Food and Drug Administration (FDA) [2]. All of
the cases to date involved patients treated for pain.





 Intrathecal, Medtronic, Inc.,




 intrathecal drug. A
more recent compilation of clinical cases appears in
the companion article by Yaksh et al. [3] that ap-
pears elsewhere in this issue. Physician community
interest in the inflammatory mass phenomenon in-
creased during 2001 along with the number of re-
ported cases (Figure 1). Figure 1 illustrates each
case only once, under the year in which the mass
was diagnosed, or under the earliest date that the
event was reported and includes the five cases pre-
viously reported in an article by Schuchard et al. in
1998 [27]. The apparent increase in cases most
likely reflects heightened awareness in the medical
community and increased reporting by physicians
after a January 2001 “Dear Doctor” mailing [3] and
after the publication of abstracts and presentations
at scientific meetings [4].
A preliminary life-table estimate of risk for oc-
currence of an inflammatory mass revealed that the
risk increased over time [3]. Owing to the voluntary
nature of case reports and uncertainties regarding
the denominator, the life-table calculations proba-
bly underestimate the risk of developing a catheter-
tip mass. Thus, the long-term usage and efficacy of
intrathecal drug therapy was another factor that
contributed to the apparent increase in cases. A
growing number of patients were at risk because
they were exposed to intrathecal analgesic drugs for
greater periods of time.
The recent convergence of physician and scien-
tific interest, the apparent increase in the number
of cases, and the availability of new preclinical (ani-
mal) data motivated the authors to form a consensus
panel to address the following issues: First, to sum-
marize the pertinent preclinical (animal) and human
data and to evaluate hypotheses regarding etiology
of catheter-tip inflammatory masses in the com-
panion article [3]; Second, to provide recommenda-
tions for clinicians about the detection and imaging
diagnosis of such masses; Third, to provide guid-
ance for physicians in the treatment of patients with
catheter-tip masses; and Finally, to present infor-
mation that may guide future studies that may help
physicians prevent the occurrence or mitigate the




Fourteen panel members contributed to this article:
nine anesthesiology-pain specialists (MC, TD, SDuP,
MH, EK, JR, PS, KDW, and MW) and five neuro-
surgeons (KB, RJC, KF, SH, and OS). All of the
physicians are experienced in the use of intrathecal
drug therapy to treat patients with chronic intractable
pain caused by cancer or noncancer-related condi-
tions. Their diverse backgrounds spanned private and
academic practices in the United States and Australia,
and included implanters of devices marketed by dif-
ferent manufacturers. This report includes laboratory
Figure 1 Reports of inflammatory mass cases by year of occurrence, 1990–2001.
 




and clinical data, where available, as well as the col-
lective assessments and recommendations of these
experienced intrathecal analgesia therapists.
 
Etiology of the Inflammatory Masses
 
The etiology and precise pathophysiologic mecha-
nism(s) that leads to the formation of catheter-tip in-
flammatory masses remains to be defined. Evidence
that supports or refutes various etiologic hypotheses
is examined in more detail in the companion article
[3]. The preponderance of animal experimental data
to date suggests that an inflammatory response oc-
curs after certain drugs, most commonly opioids, are
administered into the intrathecal space [2,3].
While there is evidence that opioids can incite an
inflammatory response in brain/spinal cord tissue,
the mechanism(s) remains unclear. Morphine can act
as a mitogen and activate a mitogen-activated protein
kinase cascade, thus activating lymphocyte activity [5,6].
Alternatively, opioids cause human endothelial cells,
granulocytes, and monocytes to release nitric oxide,
which in turn might, in the presence of mesangial
cells, lead to monocyte migration [7–9]. Finally, mor-
phine has been shown to enhance cytokine formation,
leading to an inflammatory cell response [10]. Whether





naloxone reversible remains to be determined [11].
Endothelial cells in blood vessels, brain, or spinal
cord tissue have “tight junctions,” meaning that the
cell membrane of each endothelial cell is tightly ad-
herent to the cell membranes of the adjacent endo-
thelial cells. Thus, under normal circumstances,
large molecular weight molecules cannot pass be-
tween endothelial cells and extravasate in the sur-
rounding interstitial space. This is the reason that
intravenous contrast for radiologic procedures does
not “enhance” or accumulate in the normal brain or
spinal cord tissue. Enhancement of the masses on
magnetic resonance imaging (MRI) scans, after in-
travenous injection of contrast, in the situation of a
granuloma thus indicates a lack of tight junctions in
the masses’ vascular supply [2,12–14].
This observation is consistent with the blood-
borne origin of inflammatory cells that composed
the human surgical specimens and all of the inflam-
matory masses that were examined histologically
during the course of animal studies ([3], Hassen-
busch S and Yaksh T, personal observations). The
ability of inflammatory cells to migrate through the
walls of small dural or meningeal vessels outside the
blood–central nervous system (CNS) barrier also is
consistent with the lack of CNS toxicity, apart from
extrinsic compression. Preservation of an arachnoid
plane between the granuloma and the spinal cord
also suggests an origin from extra-axial tissues. Lit-
erature and anecdotal reports also have described
masses that arise after chronic opioid administra-
tion in other non-CNS locations that include the
epidural space and the subcutaneous tunnel at the
site of a catheter break or disconnection ([15–18],
Coffey RJ and Follett K, personal observations).
Human clinical reports and animal studies strongly
support the hypothesis that injury to the spinal cord
or nerve roots was produced by the size and mass
effect of the inflammatory masses and not by a di-
rect neurotoxic effect of preservative-free opioids
and other drugs ([3], Hassenbusch S, and Yaksh T,
personal observations). The intraspinal masses that
arose after the intrathecal administration of chemi-
cally contaminated drugs or drugs that were com-
pounded in bulk from erroneously labeled contain-
ers appear to have been a different, very rare
problem [19]. Catheter material might be a con-
tributing factor, since most granuloma reports are
associated with the most common material for
catheters, silicone elastomer (silastic). However, the
much lower frequency of polyurethane-material
catheter implantation, especially in combination
with constant-rate infusion pumps rather than the
more common variable-rate pumps, makes it very
difficult to assess catheter material and/or pump
flow characteristics as etiologic agents. The pre-
ponderance of negative cultures and the absence of
acute inflammatory cells in surgical specimens
made infection an unlikely cause in most cases. The
three positive cultures reported in the literature
may have been surgical or environmental contami-
nants [1,13]. So far, a catheter-tip mass caused by
an infectious agent has not been found among the
other cases that we reviewed. Even though infec-
tion is an unlikely cause, we recommend that physi-
cians continue to perform microbiological cultures
and stains of pertinent specimens (e.g., cerebrospi-
nal fluid (CSF), access port CSF aspirates, the cath-
eter tip, pump reservoir contents, samples of ab-







A relevant neurological history and examination
should be documented in the patient’s medical
record before implantation of an intraspinal drug
administration system. This forms a baseline for
comparison in the event that new symptoms or






tip mass. At the time of implantation, the three-
dimensional location of the intrathecal catheter tip,
based upon the results of biplane radiographic
imaging, should be documented in the medical
record. Routine postimplantation office visits and
refill sessions provide an opportunity, when appro-
priate to the patient’s care, to record a brief interval
history and perform a neurological examination of
the patient’s lower extremity motor, sensory, and
reflex functions, as appropriate. The patient inter-
view should include specific questions about any
changes in bowel and bladder function.
Subtle prodromal symptoms and signs during
early growth of catheter-tip masses described in
previous reports have included diminishing analge-
sic effects (loss of previously satisfactory pain relief)
and remarkable or unusual increases in the patient’s
underlying pain. Another feature of many cases was
that patients required unusually steep or frequent
dose escalations to recapture analgesic effects. In
some cases, dose escalations and sizable drug bo-
luses reduced the patient’s pain only temporarily or
to a lesser degree than previous experience pre-
dicted. When the catheter tip was located in the
thoracic spinal canal, early symptoms of an extra-
axial inflammatory mass sometimes included tho-
racic radicular pain that simulated intercostal neu-
ralgia or cholecystitis. Catheter-tip masses in the
lumbar region sometimes simulated nerve root com-
pression from a herniated intervertebral disc or spi-
nal stenosis.
Although fluctuations in patients’ subjective symp-
toms and underlying pain levels are common after
the implantation of drug delivery systems, the occur-
rence of new or extraordinary complaints that re-
quire unexpected analgesic dose changes should alert
physicians to consider a catheter-tip mass among
other possibilities in the differential diagnosis. Grad-
ual, insidious neurological deterioration weeks or
months after the appearance of subjective symptoms
was the most common clinical course before the on-
set of myelopathy or cauda equina syndrome in cases
reported to date [2]. Awareness of the phenomenon
and maintenance of an index of suspicion are impor-
tant factors to help physicians detect such inflamma-
tory masses early in the clinical course.
Overt symptoms and findings that warrant
prompt investigation to rule out the presence of a
catheter-tip mass include changes in the patient’s
baseline neurological condition, such as: Motor
weakness, including gait difficulties; Sensory loss,
including proprioceptive loss; Hyper- or hypoac-
tive lower extremity reflexes; and Any evidence of
bowel or bladder sphincter dysfunction. Suspicious
subjective symptoms include new or different re-
ports of numbness, tingling, burning, hyperesthe-
sia, hyperalgesia, or the occurrence of pain (espe-
cially radicular pain that corresponds to the level of
the catheter tip) during catheter access port injec-
tions or programmed pump boluses. Pain upon in-
jection into the catheter, which may be encoun-
tered during system troubleshooting procedures,
should alert the physician to discontinue the proce-
dure and perform a diagnostic imaging study as
soon as possible.
The authors recommend that physicians con-
sider the following actions if they detect symptoms
and signs suggestive of a catheter-tip mass. First,
review the patient’s current complaints, history,
and neurological examination thoroughly. Second,
nonsurgical pain specialists should consider a con-
sultation that includes a review of imaging studies
with a neurosurgeon. And third, the physician
should arrange the timely performance of a defini-
tive diagnostic imaging procedure to confirm or
rule out the suspected diagnosis. Treatment, like-
wise, should be started in a timely manner. Labora-
tory tests and electromyography or nerve conduc-




Physicians should have a low threshold for per-
forming an imaging study to confirm or rule out
the presence of a catheter-tip mass in patients with
suspicious symptoms or physical findings. Illustra-
tions of catheter-tip inflammatory masses identified
on MRI and/or computed tomographic (CT)-myel-
ogram images appear in the case reports by Bejjani,
Blount, Cabbell, North, and their respective col-
leagues [1,3,12–14]. Unless medically contraindi-
cated, MRI with and without intravenous gadolin-
ium contrast enhancement or CT-myelogram is
the imaging procedure of choice. Physicians should
follow their customary safe procedures to assure
that the MRI procedure does not turn off the pump
or otherwise alter its programming. Catheter-tip





-weighted images. The mass appears
as an enhancing lesion having the tip of the drug
administration catheter embedded within it. The
catheter may be difficult to see on some MRI scans,
depending upon the pulse sequence, imaging plane,
and slice thickness. Correlation between MRI scans
and biplane radiographs is strongly recommended
to identify the location of the catheter tip. Readers
are cautioned not to overinterpret MRI artifacts
caused by the radio-opaque metal marker (e.g., tita-
nium) that is embedded in the tip of some closed-
 




end catheters. The helical titanium wire embedded
within the wall of other catheter models also might
cause imaging artifacts. Metallic artifacts on MRI





weighted images. Absolute or relative contraindica-
tions to MRI include the presence of a cardiac
pacemaker, certain prosthetic heart valves, certain
neurostimulation devices, gadolinium contrast al-
lergy, and claustrophobia.
In patients who have MRI contraindications,
such as implanted cardiac pacemakers, spinal cord
stimulation systems, or spinal instrumentation that
obscures the MRI scan, high resolution CT-myel-
ography provides an excellent means of detecting
catheter-tip masses. CT-myelography using approved,
nonionic, water-soluble contrast material injected
via a lumbar puncture has identified catheter-tip
masses successfully in all cases in which the tech-
nique was used. Physicians who plan to image the
spinal canal and evaluate the infusion system’s con-
tinuity by injecting contrast material through a
catheter access port should consider the following
factors beforehand. One concern is to avoid in-
trathecal drug overdose, depending upon the amount
of drug in the catheter and access-port dead space.
This factor is important if a preliminary attempt to
aspirate CSF through the access port was unsuc-
cessful. Another consideration involves the possi-
bility of injecting fluid and contrast material di-
rectly into the mass. Theoretically, that action
could inflate the mass and further compress the spi-
nal cord or nerve roots if a large mass already had
compromised the spinal canal. Finally, physicians
should remember that access port procedures can
leave the catheter dead space and the access port
devoid of drug unless deliberate steps are taken to
refill the catheter at the end of the procedure. The
importance of such steps depend upon the patient’s
condition, the flow rate of the pump (hence, the
time lapse until drug infusion resumes), and the
specific drug(s) and dose(s) being infused.
Other imaging-based system troubleshooting meth-
ods are not recommended. These include pump cis-
ternograms, which consist of filling the pump res-
ervoir with dilute, water-soluble myelographic
contrast material or indium-DTPA, a radionuclide
tracer, and allowing the pump to infuse the reser-
voir contents for a number of hours or days. Pump
cisternograms utilize an imaging modality (CT or
nuclear medicine scan) to provide information about
the condition of the spinal canal and flow through
the pump and catheter system. Given the time-con-
suming nature of such studies, their uncertain in-
terpretation, and the urgency of establishing the
presence of a catheter-tip mass once that diagnosis
is suspected, the authors recommend use of con-
ventional MRI or CT-myelography to promptly
confirm or rule out the diagnosis.
 
Treatment of the Mass and Management of the Drug 
Infusion System
 
Optimal patient treatment and infusion system
management should take into account the patient’s
clinical condition, the physician’s experience and





do no harm). Once an imaging study confirms the
presence of a catheter-tip mass, the physician must
decide whether to remove the mass and whether or
not to remove part or all of the drug infusion sys-
tem (Figure 2). If the decision is made to leave the
infusion system in place, the responsible physician
eventually must decide whether to continue in-
trathecal therapy and whether to change the dose,
concentration, or even the drug(s) being infused.
Some patients may require the substitution of
oral, transdermal, or parenteral opioid medications.
Depending upon the drug(s) and dose(s) that they
received previously, the management or prevention
of drug withdrawal may require hospitalization, re-
gardless of whether surgery is planned to remove the
mass, or to remove or revise the infusion system.
 
Treatment of Catheter-Tip Inflammatory Masses
 
Deliberate planning can minimize the interval be-
tween the diagnosis of a catheter-tip inflammatory
mass and its definitive treatment. Timely treat-
ment, in turn, may help to avert permanent neuro-
logical injury. A history of progressive neurological
symptoms or deficits and an imaging diagnosis of a
large inflammatory mass that compromises the spi-
nal canal should alert the physician to hospitalize
the patient emergently, stop the drug infusion, and/
or empty the drug reservoir, depending on the
model of pump. Stopping certain programmable
pumps for longer than a few days can cause the ro-
tor to stall, making it impossible to restart the de-
vice. If resumption of therapy is anticipated, such
pumps may be filled with preservative-free saline





mL/day). Whenever necessary, physicians who are
not neurosurgeons should request a neurosurgical
evaluation of the patient and review of the perti-
nent imaging studies as appropriate.
 
Surgical Removal of the Mass
 
The most commonly reported treatment for masses






cal deficits was complete or subtotal surgical removal.
Patients with apparently fixed deficits of short dura-
tion also have been operated upon because of con-
cern that delayed treatment could foreclose the possi-
bility of neurological recovery [1,2,12–14,20–22].
Surgical intervention to remove the mass and/or de-
compress the spinal canal has restored neurological
function or prevented further neurological deteriora-
tion in several reported cases [2]. The extent of resec-
tion was limited in some cases owing to adhesions to
the spinal cord or nerve roots or because of the ven-
tral location of a mass beneath the thoracic spinal
cord. Because the masses were not neoplastic, in sev-
eral cases the postoperative residual mass gradually
shrank or disappeared over time [2,3].
 
Treatment of the Mass Without Surgical Removal
 
In contrast to the cases that presented with paraple-
gia or progressive myelopathy, a number of mini-
mally or mildly symptomatic patients had small
masses that were diagnosed during investigation of
diminished analgesic efficacy or other subjective
complaints. The masses did not significantly com-
press neural structures, nor compromise neurologi-
cal function, and were managed safely and success-
fully without open surgical decompression or removal
of the mass. However, the treatment of such pa-
tients did include the prompt discontinuation of in-
trathecal drug administration into the mass through
the affected catheter. We have personally treated
patients and have reviewed cases that verify the suc-
cess of this mode of therapy in appropriately se-
lected patients. Shrinkage or disappearance of the
mass was documented on follow-up imaging studies
after an interval of 2–5 months [2]. Consequently,
catheter-tip inflammatory masses that are detected
early in the clinical course can be treated safely and
effectively by maneuvers directed at the drug infu-
sion system.
 
Management of the Drug Infusion System
 
Permanent removal of the pump and/or intrathecal
catheter was the most common method to deal with
the infusion system in previous reports (36 of 92
cases) [2,3]. However, removal of infusion system
components often accompanied surgical resection
of the mass (32 of 92 cases) [2,3]. Our experiences
and review of cases reported to date strongly sug-
gest that the presence of a catheter-tip inflamma-
Figure 2 Management algorithm for intrathecal inflammatory masses.
 




tory mass should not automatically lead to pump or
catheter removal and permanent cessation of in-
trathecal therapy. Management strategies that per-
mit therapy to continue after only a brief interrup-
tion are consistent with reports that masses have
disappeared or decreased dramatically in size after a
variety of interventions directed at the involved
catheter. These include: 1) Removal of the involved
catheter and placement of a new one during the
same operation or at a later date; 2) Disconnection
of the involved catheter from the pump, leaving the
intraspinal segment undisturbed, and placement of
a new intraspinal catheter segment at the same op-
eration or at a later date; and 3) Withdrawal of the
involved catheter to position its tip below the mass.
Each of the treatment options listed here causes
cessation of drug infusion into the mass. Continued
drug infusion into a progressively symptomatic, but
unrecognized, catheter-tip mass was associated with
progressive neurological injury in several reported
cases [2,20]. Bearing in mind the relatively short
periods of postoperative observation to date, one
case has been reported that described a new mass
that arose on a replacement catheter [14].
The article by Cabbell et al. [14] is especially il-
luminating in this regard. A long-term spinal infu-
sion patient who developed right leg weakness/
numbness was found to have a T10 catheter-tip
mass that eventually required resection, because the
symptoms/findings did not resolve despite removal
of the catheter. At the patient’s request, intrathecal
morphine was started again for pain control, but,
three years later, the patient developed right leg
pain and clumsiness and was found to have an intra-
dural mass at T12–L1. This time, however, close
clinical observation and MRI corroborated regres-
sion of this mass over 2 months of saline infusion
via the spinal infusion pump. After regression of
this mass, the pump was filled with hydromorphone
and no additional granuloma issues were observed,
at least up until the time that the paper was submit-
ted. One theoretical treatment that is not recom-
mended by the authors would be to attempt to aspi-
rate the contents of the mass through the catheter
or pump access port. Although several case reports
described masses having liquid or necrotic con-
tents, no data suggest that the material can be aspi-
rated through a hypodermic needle or even through
the catheter lumen. A single patient reportedly was





 solution (Wyeth–Ayerst, Philadelphia, PA), a
bovine testicular hyaluronidase enzyme, into the
mass via the pump [2]. Neither of these agents is
approved for intrathecal use, the patient’s outcome
 
was not reported, and the authors advise against
that mode of therapy.
Operations on the infusion system in patients
who harbor an intraspinal mass, especially proce-
dures that involve manipulation of the affected
catheter or implantation of a new one, should be
performed under fluoroscopic monitoring with the
patient under local anesthesia and minimal seda-
tion. Lower extremity motor and sensory function
should be assessed periodically during the proce-
dure. Because catheters labeled for chronic intra-
thecal use are radio-opaque, the level of the tip can
be monitored fluoroscopically. Removal or partial
withdrawal of the involved catheter in 12 reported
cases and in the authors’ experience did not cause
spinal cord or nerve root injury or intraspinal hem-
orrhage when only gentle traction was applied [2].
The consensus panel recommends abandonment of
efforts to withdraw the catheter if force beyond
gentle traction is required and/or if the patient re-
ports intraoperative symptoms that indicate dis-
placement of the mass. When that occurs, and if
the patient’s neurological condition permits, we
recommend ligation of the affected catheter and
anchoring it to the lumbodorsal fascia. An alterna-
tive, if warranted, is to remove the catheter during
open surgical exposure of the mass.
 
Selection of Drugs and Doses
 
The decision whether to revise or replace the in-
volved catheter soon after diagnosis and the decision
whether and when to resume intrathecal drug infu-
sion depend upon the patient’s neurological status
and how well he/she tolerates suspension or cessa-
tion of intrathecal therapy. The shortest interval on
record before documented shrinkage of a catheter-
tip mass was almost 2 months (7 weeks). Intervals of
6 months or longer were reported in other cases, but
the time between imaging studies was not stated.
Still, waiting for follow-up imaging to confirm shrink-
age of the mass before resuming intrathecal therapy
would commit the patient to a drug holiday lasting a
minimum of almost 2 months.
Regardless of the timing of catheter replacement
or revision, most physicians positioned the catheter
two or more vertebral segments away from the level
of the mass. Often they elected to place the cathe-
ter near or below the conus medullaris (L–1 or
L–2), although it should be noted that this might
decrease the efficacy of the treatment, particularly
with the use of lipophilic drugs. Reports also indi-
cate that most patients experienced improved pain
control at lower drug doses after replacement or re-






establishment of drug infusion directly into the
subarachnoid space, as opposed to within the in-
flammatory mass, explains the recapture of analge-
sic effects in these patients. A related explanation
may be that the mass had physically blocked CSF
and drug flow. Removal of the affected catheter
from within the mass may decompress the spinal
canal just enough to permit CSF and drug to circu-
late more effectively.
Published reports and anecdotal reports have de-
scribed a variety of intrathecal drug management
strategies in patients who had been treated for a
catheter-tip mass. Each of the authors who has per-
sonally treated such patients either changed the
drug being infused or decreased the concentration
of the original drug upon resuming therapy. Al-
though several opioid drugs, local anesthetic agents,
and clonidine currently are administered through
intrathecal infusion systems and in various combi-
nations to treat patients with intractable pain, only






Hill, NJ), is labeled for chronic intrathecal use.
When considering a change from one opioid drug
to another, physicians should take analgesic po-
tency into account, as well as the available safety
data and prescribing information and the expected
effects of a different catheter position on the distri-




 lipophilic agents [23].
 





Physicians should consider the interplay of phar-
macological and anatomic factors in the placement
of intrathecal catheters. Chronic infusion of the la-
beled formulation of morphine sulfate, a hydro-
philic compound, into the lumbar thecal sac should
achieve satisfactory drug levels and analgesic effi-
cacy regardless of the dermatomal level of the pa-
tient’s pain. Second-line agents commonly used to
recapture efficacy in difficult cases include hydro-
morphone, which is unlabeled for chronic intrathe-
cal use, is slightly less hydrophilic than morphine,
and has a potency-adjusted efficacy profile similar
to morphine [23]. In contrast, fentanyl, sufentanil,
and local anesthetic drugs are more lipophilic than
morphine and would not be expected to produce
worthwhile analgesia if infused several segments
away from the spinal segment(s) that mediates the
patient’s pain.
The clustering of cases in some practices and the
absence of cases in others has raised the issue of
whether different levels of vigilance (e.g., asymp-
 




intrathecal drug prescribing practices influenced the
detection and/or occurrence of a catheter-tip masses.
Conversely, the clustering in some geographic areas
or groups might overestimate the true incidence be-
cause of radiologists who are sensitized to observe
for any catheter-tip abnormalities, regardless of whether
the abnormalities represent true granulomata or
simply radiologic abnormalities from the catheter-
tip material. At present, none of the available evi-
dence suggests that different opioid drugs are asso-
ciated with different levels of risk for the formation
of catheter-tip inflammatory masses. Only three re-
ported patients exclusively received opioid drugs
other than morphine sulfate or hydromorphone
throughout their clinical course [2–4]. The influ-
ence of opioid–clonidine, opioid–bupivacaine, or other
unlabeled admixtures on mass formation in humans
also is unclear. Nineteen of 92 patients (20%) re-
ceived an opioid–clonidine or –bupivacaine admix-
ture, either at the time a mass was diagnosed or ear-
lier in their clinical course [3]. Although data from
two pain management centers (Cousins M, personal
observation, Buchser E, personal communication)
and one series of experiments (Yaksh T, personal
observation) suggest that clonidine- or bupivacaine-
containing admixtures may diminish the risk of in-
flammatory mass formation, the authors believe that
it is premature to draw firm conclusions or make
recommendations at this time.
 
Drug Concentration and Dose
 
A broad consensus exists within the pain manage-
ment medical community that intrathecal opioids
should be prescribed and maintained at the lowest
effective dose for as long as possible. [24] Opioid–
clonidine and/or –bupivacaine admixtures eventually
may be approved as safe and effective for long-term
intrathecal use. If such admixtures also are found to
have morphine- or opioid-sparing effects (long-term
analgesia at lower opioid-equivalent doses), combi-
nation therapy may provide part of the solution to
prevent or forestall inflammatory mass formation.
Intrathecal drug dose escalation during the pro-
dromal period before the diagnosis of many cathe-
ter-tip mass cases has confounded attempts to de-
termine whether the administration of high-dose,
high-concentration opioid medications contributed
to the formation of the inflammatory mass or
merely reflected the clinicians’ response to waning
efficacy. The results of animal studies in two mam-
malian species that we reviewed in our companion
article provide a partial answer [3]. Those studies
revealed an apparent dose or concentration re-
sponse with respect to the formation of inflamma-
 




tory masses in both dogs and sheep, although the
experimental design could not discriminate an ab-
solute dose effect from the effects of concentration.
In light of the human and animal data, it still ap-
pears prudent to keep the intrathecal morphine
concentration as low as possible and/or practical.
At least part of the impetus to employ high con-
centration opioid drugs in intrathecal drug pumps
has been the limited volume of the reservoir in some
programmable pumps and the relatively high daily
infusion rate in some constant flow systems. Those
limitations cause patients whose intrathecal opioid
requirements have escalated over time to require un-
acceptably frequent pump refill appointments unless
the physician employs relatively high-concentration
morphine or more potent agents (such as hydromor-
phone). As a consequence, patient risk factors may
be interdependent. The longer a patient remains on
intrathecal therapy (an apparent risk factor), the
more likely that patient is to require a higher opioid
dose that is prescribed as a high-concentration for-
mulation (another apparent risk factor) in order to
maintain acceptable refill intervals.
Formulations of preservative-free morphine for




25 mg/mL commonly are compounded at hospi-
tal or contract pharmacies from nonsterile mor-
phine sulfate powder to create a solution that is





vances in pump design may provide a partial solu-
tion to the compounding dilemma. Recently ap-
proved constant-flow-rate pumps are available with





0.5 mL/day). The next generation of
programmable infusion pumps also will have larger





0.1 mL/day. Thus, larger pump reservoir
volumes allow physicians a variety of means to treat
patients using lower morphine concentrations while
maintaining acceptable refill intervals. Still, the is-
sue remains unsettled whether the absolute opioid
dose, the infused opioid concentration, or both (or
neither) influence a patient’s risk for formation of a
catheter-tip inflammatory mass. Follow-up animal
studies beyond those described in our companion
article [3] may help to answer this question. For ex-
ample, one could determine whether the same daily
dose of intrathecal opioid medication that reliably
caused catheter tip mass formation in an experi-
mental model had the same effect when adminis-
tered in a 5 to 10 times larger volume (0.2–0.1
times concentration). In addition, a cross-sectional
population study that included neuroimaging find-
ings on 300 to 500 asymptomatic patients treated
with long-term intrathecal opioid therapy might
yield complementary data on the influence of drug




MRI or CT-myelographic screening of patients on
intrathecal therapy for chronic pain who are other-
wise asymptomatic is not supported by present lit-
erature, but physicians can individualize this to
their practice. However, as mentioned earlier, phy-
sicians should maintain a low threshold for order-
ing such studies in patients perceived to be at risk.
Even subjective or relatively minor symptoms in a
patient on long-term intrathecal opioid therapy
may justify an imaging study, especially if recent
dose escalations, loss of pain relief, or new radicular
pain raise the possibility of a catheter-tip mass as
part of the physician’s differential diagnosis.
 
Implant Technique and Catheter-Tip Location
 
Individual patient considerations, such as neoplas-
tic involvement of the spine or extensive previous
surgery, sometimes require the placement of drug
infusion catheters within the thoracic, or even the
cervical, spinal canal. If a lipophilic drug is to be in-
fused, it may be necessary to position the catheter
tip near the spinal cord dermatomal level corre-
sponding to the location of the pain in the body.
However, purely anatomic considerations reveal
that a catheter tip positioned above the conus med-
ullaris can place the spinal cord at risk for injury in
the event that a mass develops. In contrast, a lum-
bar-level catheter tip, placed below the conus med-
ullaris, should not cause a spinal cord injury, even if
a mass were to develop. In addition, the nerve roots
of the cauda equina are invested with Schwann cell
myelin, are part of the peripheral nervous system,
and are more resistant to injury than the central ax-
ons within the spinal cord. In previous reports,
lumbar catheter-tip masses that affected the cauda
equina caused less severe neurological deficits that
were more likely to improve after surgery or other
treatments than higher catheter-tip masses that in-
jured the spinal cord. Despite all these theoretical
considerations, it is not clear whether there is a
greater risk with a thoracic catheter tip. In some
situations, a thoracic catheter is needed for the in-
fusion of a lipid-soluble drug or a local anesthetic
agent. The physician should always consider all
these factors in the determination of the final loca-
tion of the permanent catheter’s tip.
The surgical techniques used during catheter
implantation and the dorsal–ventral location of the
catheter within the spinal canal did not appear to






However, two of the authors have hypothesized
that catheter tips located in the thoracic region may
indirectly cause higher local drug concentrations
around the catheter tip than one would expect
[2,25,26]. High local drug concentrations may set
the stage for a localized inflammatory response and





Despite the lack of controlled trials or large epidemio-
logical studies, the panel has reviewed a significant
amount of clinical and preclinical data that support the
following conclusions and recommendations regard-
ing the detection and treatment of catheter-tip inflam-
matory masses, as summarized in Table 1. Our analy-
sis of the various hypotheses regarding etiology also
leads to recommendations on prevention, mitigation
of neurological sequelae, and areas of future research.
Inadequately treated chronic pain is a serious con-
dition that carries its own risks and morbidity. In that
context, the risk of developing a catheter-tip mass as
a consequence of long-term intrathecal drug admin-
istration should remain acceptable, provided that the
treatment is effective. Physicians should select and
screen patients carefully to maximize the likelihood
of therapeutic efficacy. Physicians also should con-
sider the catheter-tip mass phenomenon in the risks
of the procedure and the long-term therapy.
Thorough baseline evaluation and attentive fol-
low-up form the foundation for early diagnosis in
the event that a catheter-tip mass develops. Physi-
cians should remain alert to the signs and symp-
toms described in this article and others and should
maintain an index of suspicion when they encoun-
ter otherwise unexplained patient symptoms or






raphy is just as effective in confirming the diagnosis
 
in individuals for whom MRI is contraindicated
(e.g., patients with cardiac pacemakers and certain
other prosthetic devices).
A number of acceptable treatment options are
available. The selection predominantly depends
upon the patient’s clinical condition. Surgical re-
moval or decompression is not mandatory in all pa-
tients, especially those who have few or mild symp-
toms. When a patient presents with a profound or
progressive neurological deficit, the authors recom-
mend surgical consultation and participation in the
decision-making process.





thoracic spinal canal cannot be relied upon to prevent
the development of an inflammatory mass, lumbar
placement theoretically might mitigate the neurolog-
ical consequences if a mass occurs. This is because
the spinal cord, which is more susceptible than the
cauda equina to permanent injury from extrinsic
compression, ends in the upper lumbar region.
Given the unsettled nature of the evidence regard-
ing the etiology of catheter-tip inflammatory masses,
recommendations about prevention also are specula-
tive. Still, such masses have not been reported in pa-
tients with lumboperitoneal shunts, nor in those who
have received intrathecal baclofen. This leaves opioid-
drug-related phenomena as a significant component
of the most plausible hypothesis. With that in mind,
the authors repeat the same recommendation regard-
ing intrathecal opioid prescribing practices that has
been made for decades: Keep the dose and concen-
tration as low as possible for as long as possible while
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1. Document a thorough baseline evaluation.
2. Document three-dimensional location of the intrathecal catheter tip at implantation.
3. Provide attentive follow-up and remain alert to diminishing analgesic effects, loss of previously satisfactory pain relief, remarkable or 
unusual increases in the patients underlying pain, steep or frequent dose escalations, or neurologic symptoms suggestive of an 
inflammatory mass.








1. Mildly symptomatic patients can be treated conservatively by drug cessation through the catheter into the mass.




1. Consider placement of the catheter tip in the lumbar thecal sac.
2. Keep the drug dose and concentration as low as possible for as long as possible while still achieving adequate analgesia.
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